DEA Reschedules CBD to Schedule V Drug The DEA has rescheduled some CBD products from Schedule I to Schedule V, marking a major turning point in the CBD industry.
DEA Reportedly Wants More Cannabis, Fewer Opioids, in 2019 While the DEA has openly been against the production and use of cannabis for any reason, the opioid epidemic is begin to change their approaches.
